Show simple item record

dc.contributor.authorZhou, Cong
dc.contributor.authorTaylor, S
dc.contributor.authorTugwood, Jonathan D
dc.contributor.authorSimpson, Kathryn L
dc.contributor.authorJayson, Gordon C
dc.contributor.authorSymonds, P
dc.contributor.authorPaul, J
dc.contributor.authorDavidson, Susan E
dc.contributor.authorCarty, K
dc.contributor.authorMcCartney, E
dc.contributor.authorRai, D
dc.contributor.authorDive, Caroline
dc.contributor.authorWest, Catharine ML
dc.date.accessioned2019-06-04T09:44:28Z
dc.date.available2019-06-04T09:44:28Z
dc.date.issued2019en
dc.identifier.citationZhou C, Taylor S, Tugwood J, Simpson K, Jayson GC, Symonds P, et al. Dynamics of circulating VEGF-A predict benefit from anti-angiogenic cediranib in metastatic or recurrent cervical cancer patients. Br J Clin Pharmacol. 2019.en
dc.identifier.pmid30980733en
dc.identifier.doi10.1111/bcp.13965en
dc.identifier.urihttp://hdl.handle.net/10541/621827
dc.description.abstractBACKGROUND AND PURPOSE: There is a need for predictive and surrogate response biomarkers to support treatment with anti-angiogenic VEGF inhibitors. We aimed to identify a minimally-invasive biomarker predicting benefit from cediranib pre-treatment or early during treatment in patients with recurrent or metastatic cervical cancer. EXPERIMENTAL APPROACH: Blood samples were collected before treatment, during treatment and upon disease progression where appropriate from patients enrolled in CIRCCa, a randomised phase II trial of carboplatin and paclitaxel with or without cediranib. Plasma concentrations of VEGF-A, VEGF-R2, Ang1 and Tie2 were measured using multiplex ELISA. Pre-treatment and temporal changes of the biomarkers were investigated using proportional hazard regression and unsupervised clustering analysis. KEY RESULTS: Samples (n=556) from 52 patients were analysed. VEGF-R2 (p=0.0006) and Tie2 (p=0.04) were down-regulated following cediranib, while VEGF-A (p=0.0025) was up-regulated. High ECOG performance status (p=0.02, HR=2.15, 95%CI 1.13-4.09) and low pre-treatment Tie2 concentrations (p=0.003, HR= 0.57, 95%CI 0.39-0.83) were independent prognostic factors associated with reduced progression-free survival. Two patterns of changes in VEGF-A following cediranib were identified. Patients with elevated VEGA-A in the first 3 treatment cycles, regardless of magnitude, had reduced progression-free survival in the placebo arm but improved survival with the addition of cediranib (p=0.019, HR= 0.13, 95% CI 0.02-0.71). CONCLUSIONS AND IMPLICATIONS: Patterns of early elevation in plasma VEGF-A should be studied further as a potential biomarker to predict treatment benefit from cediranib.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1111/bcp.13965en
dc.titleDynamics of circulating VEGF-A predict benefit from anti-angiogenic cediranib in metastatic or recurrent cervical cancer patientsen
dc.typeArticleen
dc.contributor.departmentDivision of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UKen
dc.identifier.journalBritish Journal of Clinical Pharmacologyen


This item appears in the following Collection(s)

Show simple item record